Insider Trading disclosures for PharmaCyte Biotech Inc
The latest disclosure was made by Robert Weinstein in PharmaCyte Biotech Inc where a trade of 38,009
Stock Option (Right to Buy) done
was reported to US exchanges on April 30, 2024.
Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company.
A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).
| Client Name |
Client Category |
Action |
Reported to Exchange |
Quantity |
Post Transaction Holding |
Traded % |
Avg. Price |
Value |
Security Type |
|
Robert Weinstein
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
30 Apr 2024 |
38,009 |
38,009
|
-
|
|
-
|
Stock Option (Right to Buy) |
|
Michael M. Abecassis
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
30 Apr 2024 |
38,009 |
38,009
|
-
|
|
-
|
Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges